ARTICLE | Regulation
Commentary: Don't go there
Commentary: NICE is wrong-headed by toying with R&D-based reimbursement
March 17, 2014 7:00 AM UTC
There are legitimate reasons to be concerned about the prices of Orphan drugs, but the worst possible way to look for a solution would be to focus on the costs of development.
That is what the U.K.'s NICE seems to be focusing on with its first Highly Specialised Technology (HST) assessment of an Orphan drug, Soliris eculizumab for atypical hemolytic uremic syndrome from Alexion Pharmaceuticals Inc...